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ABSTRACT
Biochemical markers of bone turnover are higher in young adult men than inmiddle-agedmen or young adult women. Nonetheless,
little is known about the determinants and clinical signiﬁcance hereof. The present study examined determinants of serum bone
turnovermarkers inmen around peak bonemass age, and exploredwhether bone turnover at this age predicts subsequent changes
in bone mass. We used cross-sectional and longitudinal data from 973 and 428 healthy men, respectively, aged 25 to 45 years at
baseline, including baseline procollagen type I amino-terminal propeptide (P1NP), osteocalcin, and C-terminal telopeptide of type I
collagen (CTX) from fasting serum samples, baseline questionnaire-assessed physical activity levels, and baseline and follow-up dual-
energy X-ray absorptiometry–derived areal bonemineral density (aBMD) and body composition.Mean follow-up timewas 12.4 0.4
years. At baseline, all bone turnover markers were inversely associated with total body fat mass (b –0.20, p< 0.001), and positively
with physical activity during sports activities (b 0.09, p 0.003), and, albeit not independently from fat mass, total body lean mass
(b 0.20, p 0.003). Mean annual aBMD changes in the longitudinal cohort were –0.19% 0.24% at the total body, –0.14% 0.42%
at the spine, –0.49% 0.47% at the femoral neck, and –0.25% 0.37% at the total hip (all p< 0.001). Higher bone turnover markers
at baseline were associated with larger decreases in aBMD at all measurement sites (b –0.08, p 0.081 for P1NP; b –0.16,
p 0.002 for osteocalcin; and b –0.21, p< 0.001 for CTX). In conclusion, our ﬁndings show that sports activities and body
composition, primarily fat mass, are the main identiﬁed determinants of bone turnover in men around peak bonemass age. Further,
bone turnover at this age is an important determinant of subsequent changes in bone mass, with higher levels of bone turnover
markers being associated with greater decreases in aBMD. © 2017 American Society for Bone and Mineral Research.
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Introduction
Osteoporosis-associated fragility fractures remain a majorhealth problem, leading to increased morbidity and
mortality in both men and women.(1) The main determinants
of the risk of developing osteoporosis include the acquisition of
peak bone mass on the one hand, and the rate of subsequent
bone loss on the other.(2) Bone mass acquisition occurs mainly
during childhood and adolescence, with peak bone mass being
achieved around the end of the third decade. This process is
accompanied by high levels of bone turnovermarkers, reﬂecting
linear growth at end-plates, modeling of the bone at the
periosteum, and remodeling at endosteal surfaces.(3) After peak
bone mass attainment, serum levels of bone turnover
markers decrease rapidly in women only to rise again during
and after menopausal transition, whereas they remain remark-
ably high in men, not reaching a nadir until the ﬁfth or sixth
decade of life.(4–6) The underlying mechanisms and clinical
signiﬁcance of these persistently high levels of bone turnover in
young adult men are incompletely understood. High levels of
bone turnover markers have been shown to predict greater
increases in bone mass and size during bone acquisition,(7) but
were associated with faster bone loss in postmenopausal
women and middle-aged and elderly men,(8–10) whereas no
studies have investigated this association in young adulthood.
Furthermore, studies investigating possible determinants of
bone turnover in adult men, including gonadal and adrenal
sex steroids, insulin-like growth factor I (IGF-I), parathyroid
hormone (PTH), and 25-hydroxyvitamin D [25(OH)D], are scarce
and inconclusive.(3,5,11,12)
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The present study aimed to examine determinants of serum
bone turnover markers in young adult men around the age of
peak bone mass attainment, and to explore whether bone
turnover at this age predicts subsequent changes in bone mass.
We hypothesized that (i) the relatively high levels of bone
turnover markers in these men would be associated with
parameters reﬂecting mechanical loading, and that (ii) they
would predict early changes in bone mass after completion of
growth.
Subjects and Methods
Study design and population
The present study is part of a population-based study designed
to investigate determinants of peak bone mass and subsequent
bone changes in men, including a cross-sectional and a
longitudinal component and focusing on general lifestyle, sex
hormone status, body composition, and genetic background.
The detailed design of the cross-sectional study (SIBLOS) has
previously been described.(13) Brieﬂy, 1114 healthy men aged 25
to 45 years, who had a brother within the same age range also
willing to participate, were recruited from the population
registries of the semi-rural to urban communities around Ghent,
Belgium, between March 2002 and July 2010. All participants
completed questionnaires about medical history, medication
use, education, smoking, and calcium intake.(14) After applying
the exclusion criteria, including illnesses or medication use
affecting body composition, sex hormone status or bone
metabolism, 999 men were included in the study cohort. Five
participants with nonfasting serum samples and 21 participants
with a history of fracture within 1 year were additionally
excluded from the present study, leaving a study sample of 973
men for the cross-sectional analyses. Recruitment for the
ongoing longitudinal follow-up study (SIBEX) started in
May 2014. In October 2016, 460 participants (of 678 invited)
had been re-evaluated, corresponding to a participation rate of
67.8%. Reasons for loss to follow-up included death (n¼ 4),
relocation (n¼ 102), or unwillingness to participate in the
follow-up visit (n¼ 115). Among these 460 subjects, 32 were
excluded after applying the same exclusion criteria that were
used in the cross-sectional study (rheumatic or gastrointestinal
inﬂammatory diseases, n¼ 13; myotonic dystrophy, n¼1
myasthenia gravis, n¼1 hemochromatosis, n¼1 malignancy,
n¼ 8; gastric bypass, n¼ 3; systemic corticoid use for >3
months, n¼ 7; thyroxin therapy, n¼ 3; and bisphosphonate use,
n¼ 1). Eleven of the remaining 428 participants were already
excluded from the present cross-sectional analyses, leaving a
study sample of 417 participants for the longitudinal analyses.
The study protocol was approved by the ethical committee of
the Ghent University Hospital andwritten informed consent was
obtained from all participants. The SIBEX-study was registered
on ClinicalTrials.gov (#NCT02997033).
Biochemical measurements
Venous blood samples were obtained between 8:00 a.m. and
10:00 a.m. after an overnight fast. Serum samples were stored at
–80°C until batch analysis. C-terminal telopeptide of type I
collagen [CTX; intraassay and interassay coefﬁcient of variation
(CV)  5.6%], procollagen type I N-terminal propeptide (P1NP;
CV  10%), N-mid fragment of osteocalcin (CV  6.5%),
and intact PTH (CV  4.3%) were measured using an
electrochemiluminescence immunoassay (Roche Diagnostics,
Mannheim, Germany). 25(OH)D was determined after extraction
by radioimmunoassay (DiaSorin, Stillwater, MN, USA; CV 
11.3%). Commercial assays were used to determine serum levels
of glucose (hexokinase method; CV 1.6%), insulin (CV 3.1%)
and creatinine (CV  4.0%) (Roche Diagnostics, Mannheim,
Germany), leptin (Linco Research, Inc., St. Louis, MO, USA; CV 
8.3%), adiponectin (BioVendor LM, Brno, Czech Republic; CV 
8.2%), IGF-I (Diagnostic System Laboratories, Webster, TX, USA
and Cisbio Bioassays, Codolet, France; CV  7.5%), and sex
hormone-binding globulin (SHBG; CV  7.8%) (Orion Diagnos-
tica, Espoo, Finland). Total testosterone (T; CV  5.3%) and
estradiol (E2; CV  7.2%) were determined by liquid chroma-
tography-tandem mass spectrometry (AB Sciex 5500 triple-
quadrupole mass spectrometer; AB Sciex, Toronto, Canada) as
previously described.(15) Lower limits of quantiﬁcation were
1 ng/dL for T and 0.3 pg/mL for E2. Free T and free E2 were
calculated from T, E2, SHBG, and albumin concentrations using a
previously validated equation derived from the mass-action
law.(16,17) Estimated glomerular ﬁltration rate (eGFR) was
calculated using the Chronic Kidney Disease Epidemiology
Collaboration (CKD-EPI) formula.(18) Insulin resistance was
evaluated using the homeostasis model assessment of insulin
resistance (HOMA-IR), calculated by multiplying insulin (mU/L)
and glucose levels (mmol/L) and dividing the result by 22.5.(19)
Anthropometry, muscle parameters, body composition,
and areal bone parameters
Body weight was measured to the nearest 0.1 kg in light indoor
clothing without shoes. Standing height was measured to the
nearest 0.1 cm using a wall-mounted Harpenden stadiometer
(Holtain Ltd., Crymuch, UK). At baseline, physical activity was
scored using the questionnaire developed by Baecke and
colleagues.(20) This self-administered questionnaire is used to
estimate an aggregate of the frequency, duration and intensity
of habitual physical activities during work (work index), sports
activities (sports index), and leisure time excluding sports
(leisure time index). Using this scoring system, physical activity
levels can range between 1 (minimum level) and 5 (maximum
level). Grip strength (kg) was measured at the dominant hand
using an adjustable hand-held standard grip device (JAMAR
hand dynamometer; Sammons & Preston, Bolingbrook, IL, USA).
Isokinetic peak torque of the biceps and quadriceps muscles
(Nm) was measured at the dominant limbs using an isokinetic
dynamometer (Biodex, New York, NY, USA). Body composition
(including total body fat and lean mass) as well as areal bone
parameters [including bone mineral content (BMC) and areal
bone mineral density (aBMD) at the total body (without head),
lumbar spine, and left proximal femur (total hip region and
femoral neck)] were measured at baseline and follow-up using
dual-energy X-ray absorptiometry (DXA), with a Hologic QDR-
4500A device (software version 11.2.1; Hologic, Bedford, MA,
USA). CVs for spine and hip phantoms (daily and weekly
measurements, respectively) were 0.452% and 0.798% for aBMD,
and 0.628% and 0.828% for BMC. Baseline and follow-up scans
were performed by the same well-trained and dedicated
technicians.
Statistical analyses
Descriptive data are expressed as mean standard deviation
(SD) or median (25th to 75th percentile) when criteria for
normality were not fulﬁlled. Skewed variables [bone turnover
markers, 25(OH)D, PTH, sex steroids, total body fat and lean
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mass, leptin, adiponectin, insulin, and HOMA-IR] were log-
transformed in subsequent linear models. To evaluate the
familial resemblance of bone turnovermarkers independently of
age, conditional intraclass correlation coefﬁcients (ICCs) were
calculated from linear mixed-effect models including age as a
ﬁxed predictor, and multiplied with the proportion of the total
variance not explained by age, calculated from unconditional
models and models with age as a predictor. Cross-sectional
associations between serum bone turnover markers and
smoking behavior (smoker versus nonsmoker), season of visit,
calcium intake, eGFR, hormonal parameters, physical activity,
muscle parameters, body composition, and DXA parameters at
baseline were evaluated using linear mixed-effects modeling,
with list-wise deletion of missing data and a variance
components residual correlation structure for random effects,
taking into account the interdependence of measurements
within families. Unless stated otherwise, cross-sectional analyses
were adjusted for age, height, and weight. Changes in DXA
measurements between baseline and follow-up were evaluated
using linear mixed-effects modeling with an additional unstruc-
tured covariance structure for repeated measures. To determine
if baseline bone turnover markers were independent predictors
of subsequent changes in DXA parameters, linear mixed-effects
modeling was performed with absolute annual changes in one
of the DXA parameters as the outcome and one of the baseline
bone turnover markers as the predictor variable, with additional
adjustment for the respective baseline DXA measurement,
baseline age and height, and baseline as well as changes in total
body fat and leanmass. To estimate the proportion of aBMD and
BMC changes explained by baseline bone turnover markers, R2
values were calculated from covariance parameters derived
from models including only baseline aBMD or BMC as the
predictor variable (considered the null model), models addi-
tionally including baseline age, height, and baseline and
changes in body composition, and models including these
predictors plus one of the bone turnover markers. Continuous
predictor and outcome variables were standardized in order to
obtain standardized regression coefﬁcients. Parameters of ﬁxed
effects were estimated using maximum likelihood estimation
and reported as standardized regression coefﬁcients (b) with
their respective 95% conﬁdence intervals (CIs). All analyses were
performed using SPSS version 24.0 (IBM Corp., Armonk, NY,
USA). The Benjamini-Hochberg procedure was used to control
for false discovery rate (set at< 5%).(21)After correction, cut-off p
values for statistical signiﬁcance were<0.010 for cross-sectional
and <0.036 for longitudinal analyses.
Results
General characteristics, body composition, muscle parameters,
and biochemical measurements of the cross-sectional study
sample are summarized in Table 1. The majority of the
participants (55.1%) had a normal BMI, 36.6% were over-
weight, and 8.3% were obese. None of the participants were
on antidiabetic drugs or had fasting glucose levels 7mmol/L.
Fat and lean mass relative to total mass were 19.6% 5.4%
and 76.9% 5.1%, respectively. Mean values for work index,
sports index, and leisure time index were 2.69 0.75,
2.67 0.78, and 2.68 0.58; median calcium intake was 563
(426 to 741) mg daily. Mean serum creatinine was
0.95 0.12mg/dL, with none of the participants having an
eGFR below 68.8mL/min/1.73m2.
Cross-sectional determinants of serum bone turnover
markers and associations with areal bone parameters
Bone turnover markers were highly intercorrelated, with
correlation coefﬁcients ranging between 0.63 (for P1NP and
CTX) and 0.73 (for P1NP and osteocalcin; all p< 0.001).
Independently of age, familial resemblance explained 34% of
the variance in P1NP, 29% of the variance in osteocalcin, and
28% of the variance in CTX. In unadjusted analyses, all bone
turnover markers were inversely associated with age (b¼ –0.37
for P1NP, b¼ –0.38 for osteocalcin, and b¼ –0.34 for CTX; all
p< 0.001) and weight (b¼ –0.19, b¼ –0.12, and b¼ –0.16; all
p< 0.001). We detected no seasonal variation in serum levels of
bone turnover markers (p 0.142), and besides a trend toward
lower osteocalcin in smoking versus nonsmoking participants
(geometric means 21.0 0.25 versus 22.0 0.12mg/L,
p¼ 0.012), bone turnover markers were not associated with
smoking behavior (p 0.072), calcium intake (p 0.405), or
eGFR (p 0.068).
Cross-sectional associations of bone turnover markers with
body composition, muscle parameters, and biochemical meas-
urements are shown in Table 2 (Model A). Serum bone turnover
Table 1. General Characteristics, Body Composition, Muscle
Parameters, and Biochemical Measurements of the Cross-
Sectional Study Population at Baseline (n ¼ 973)
Mean  SD or median
(25th to 75th percentile)
Age (years) 34.5  5.5
Height (cm) 179.6  6.5
Weight (kg) 80.8  11.7
BMI (kg/m2) 25.1  3.5
Total fat mass (kg) 15.4 (11.6–19.8)
Total lean mass (kg) 61.3 (56.9–66.1)
Physical activity index 2.68  0.44
Grip strength (kg) 52.7  7.9
Biceps flexion torque (Nm) 56.7  10.1
Quadriceps extension torque (Nm) 200.0  42.4
Peak jump force (kN) 2.27  0.37
P1NP (mg/L) 50.7 (41.6–63.6)
Osteocalcin (mg/L) 21.7 (18.4–26.3)
CTX (ng/mL) 0.41 (0.31–0.52)
PTH (ng/L) 33.4 (26.7–41.7)
25(OH)D (ng/mL) 18.7 (14.2–23.8)
Total T (ng/dL) 566.1 (454.6–689.5)
Total E2 (pg/mL) 20.00 (16.09–24.59)
IGF-I (ng/mL) 345.7  119.2
Leptin (mg/L) 4.1 (2.6–6.8)
Adiponectin (mg/L) 8.3 (6.3–10.9)
Glucose (mmol/L) 4.7  0.5
Insulin (pmol/L) 43.8 (31.3–62.5)
HOMA-IR 1.35 (0.90–1.93)
Physical activity was scored using the questionnaire as proposed by
Baecke and colleagues;(20) levels can range between 1 (minimum level)
and 5 (maximum level).
P1NP ¼ procollagen type I N-terminal propeptide; CTX ¼ C-terminal
telopeptide of type I collagen; PTH ¼ parathyroid hormone; 25(OH)D ¼
25-hydroxyvitaminD;T¼ testosterone; E2¼ estradiol; IGF-I¼ insulin-like
growth factor 1; HOMA-IR ¼ homeostasis model assessment of insulin
resistance.
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markers were positively associated with total body lean mass
and inversely with total body fat mass. In addition, all bone
turnover markers were positively associated with sports index,
whereas we observed no associations with either total physical
activity or work or leisure time index, nor with any of the
parameters reﬂecting muscle strength (all p 0.075). When fat
and lean mass were included in the same model, fat mass
remained an independent predictor of bone turnover (b¼ –0.19
for P1NP, b¼ –0.22 for osteocalcin, and b¼ –0.26 for CTX; all
p< 0.001), whereas the associations with lean mass lost
signiﬁcance (all p 0.095). Additional adjustment for sports
index did not alter these results (Table 2, Model B). Bone
turnover markers were generally positively associated with PTH
and inversely with leptin. In addition, P1NP was inversely
associated with fasting glucose, although this association
weakened after adjustment for body composition (ie, total
body lean and fat mass) instead of weight (b¼ –0.07, p¼ 0.013).
Besides weak positive associations of P1NP with SHBG (age,
height, and body composition-adjusted b¼ 0.08, p¼ 0.009) and
of CTX with IGF-I (b¼ 0.11, p¼ 0.001), we observed no
associations of serum bone turnover markers with sex steroids,
25(OH)D, adiponectin, IGF-I, insulin, or HOMA-IR (all p 0.045).
Furthermore, bone turnover markers were not associated with
aBMD or BMC at any of the measurement sites (all p 0.022).
Longitudinal associations between baseline bone
turnover markers and changes in areal bone parameters
Except for a small difference in baseline age (34.5 5.5 versus
35.0 5.4 years, p¼ 0.008) and P1NP levels [50.7 (41.6 to 63.3)
mg/L versus 49.3 (41.4 to 62.8) mg/L, p¼ 0.045], the 417
participants for whom follow-up data were available did not
differ from the total study population in terms of anthropome-
try, body composition, muscle parameters, DXA parameters, or
bone turnover markers. Mean follow-up time was 12.4 0.4
(range, 12.2 to 12.6) years. Changes in bone parameters between
baseline and follow-up are summarized in Table 3. Younger age
at baseline was associated with a larger aBMD decrease at the
total body (b¼ 0.11, p¼ 0.035), and with larger aBMD and BMC
decreases at the total hip (b¼ 0.19 and b¼ 0.22, both p< 0.001)
and femoral neck (b¼ 0.22 and b¼ 0.17, both p< 0.001) (Fig. 1).
Table 4 and Fig. 2 display the associations between baseline
bone turnover markers and changes in DXA parameters. Higher
levels of osteocalcin and CTX at baseline were associated with
Table 3. Areal Bone Parameters at Baseline and Follow-Up (n ¼ 417)
Baseline Follow-up Annual change Annual % change
Total body aBMD (g/cm2) 1.111 0.092 1.085 0.091 –0.002 0.003a –0.19 0.24
Total body BMC (g) 2349.1 313.7 2314.9 308.2 –2.9  7.6a –0.12 0.31
Spine aBMD (g/cm2) 1.060 0.122 1.043 0.128 –0.002 0.004a –0.14 0.42
Spine BMC (g) 76.4 12.3 75.8 12.6 –0.06 0.41a –0.07 0.53
Total hip aBMD (g/cm2) 1.078 0.137 1.043 0.128 –0.003 0.004a –0.25 0.37
Total hip BMC (g) 48.7 7.8 48.7 7.6 –0.002 0.23 0.01 0.45
Femoral neck aBMD (g/cm2) 0.885 0.129 0.829 0.116 –0.005 0.004a –0.49 0.47
Femoral neck BMC (g) 5.17 0.82 4.85 0.73 –0.03 0.03a –0.47 0.53
Annual changes in areal bone parameters were calculated as the absolute change from baseline to follow-up divided by years of follow-up. Annual %
changes were calculated as annual change divided by the respective baseline value, multiplied by 100.
aBMD¼ areal bone mineral density; BMC ¼ bone mineral content.
ap for change< 0.001.
Table 2. Cross-Sectional Associations of Serum Bone Turnover Markers With Body Composition, Physical Activity, and Biochemical
Measurements at Baseline (n ¼ 973)
P1NP Osteocalcin CTX
b (95% CI) p b (95% CI) p b (95% CI) p
Model A
Total body fat mass –0.25 (–0.36 to –0.15) <0.001 –0.20 (–0.31 to –0.09) <0.001 –0.24 (–0.35 to –0.13) <0.001
Total body lean mass 0.22 (0.09 to 0.35) 0.001 0.20 (0.07 to 0.33) 0.003 0.30 (0.17 to 0.43) <0.001
Sports index 0.13 (0.07 to 0.19) <0.001 0.10 (0.05 to 0.16) <0.001 0.09 (0.03 to 0.15) 0.003
PTH 0.06 (0.004 to 0.12) 0.037 0.11 (0.05 to 0.16) <0.001 0.07 (0.009 to 0.13) 0.023
Leptin –0.12 (–0.21 to –0.04) 0.004 –0.13 (–0.21 to –0.05) 0.002 –0.10 (–0.18 to –0.01) 0.028
Glucose –0.08 (–0.14 to –0.02) 0.008 –0.06 (–0.12 to –0.004) 0.036 0.002 (–0.06 to 0.06) 0.948
Model B
Total body fat mass –0.15 (–0.22 to –0.08) <0.001 –0.19 (–0.26 to –0.12) <0.001 –0.21 (–0.28 to –0.14) <0.001
Total body lean mass 0.04 (–0.04 to 0.12) 0.357 –0.04 (–0.11 to 0.04) 0.389 0.03 (–0.05 to 0.11) 0.474
Sports index 0.10 (0.05 to 0.16) <0.001 0.08 (0.03 to 0.14) 0.004 0.06 (0.001 to 0.12) 0.046
Model A: model including one of the bone turnover markers as the outcome and total body fat mass, total body leanmass, sports index, PTH, leptin, or
glucose as the predictor variable, with additional adjustment for age, height and weight. Model B: model including one of the bone turnover markers as
the outcome and total body fat mass, total body lean mass, and sports index as the predictor variables, with additional adjustment for age and height.
Sports index was calculated using the questionnaire as proposed by Baecke and colleagues.(20)
P1NP ¼ procollagen type I N-terminal propeptide; CTX ¼ C-terminal telopeptide of type I collagen, PTH ¼ parathyroid hormone.
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larger decreases in aBMD and BMC at all measurement sites. In
addition, higher baseline P1NP levels were associated with
larger decreases in aBMD and BMC at the total hip and spine. As
compared to models including only baseline age, height, body
composition, and changes in body composition as predictor
variables, models additionally including one of the bone
turnovermarkers increased the explained proportion of variance
in aBMD and BMC changes with up to 8%, with the largest
increases observed for models including CTX (Supporting
Table 1). Results were largely unchanged after additional
adjustment for baseline sports index or PTH. No interactions
between the bone turnover markers and baseline age were
observed for any of the DXA parameters.
Discussion
The present study investigated the determinants of serum bone
turnover markers in men around peak bone mass age, as well as
their association with subsequent changes in bone mass. Our
results indicate that among a broad range of potential
determinants and besides young age, body composition and
physical activity during sports activities emerge as the most
Fig. 1. Associations between baseline age and aBMD changes at the total body (minus head), spine, total hip, and femoral neck. Annual aBMD changes
were calculated as the absolute change frombaseline to follow-up divided by years of follow-up. Bars andwhiskers representmean annual aBMD change
and standard error per age category. ap< 0.05, bp< 0.01; cp< 0.001; analyses are adjusted for baseline aBMD value. aBMD¼ areal bone mineral density.
Table 4. Associations of Baseline Bone Turnover Markers With Annual Changes in Areal Bone Parameters
P1NP Osteocalcin CTX
b (95% CI) p b (95% CI) p b (95% CI) p
D Total body aBMD –0.13 (–0.23 to –0.03) 0.012 –0.20 (–0.30 to –0.10) <0.001 –0.31 (–0.40 to –0.21) <0.001
D Total body BMC –0.11 (–0.21 to –0.01) 0.006 –0.17 (–0.27 to –0.07) 0.001 –0.24 (–0.33 to –0.15) <0.001
D Spine aBMD –0.13 (–0.23 to –0.02) 0.015 –0.16 (–0.27 to –0.06) 0.002 –0.27 (–0.36 to –0.17) <0.001
D Spine BMC –0.11 (–0.21 to –0.03) 0.044 –0.15 (–0.25 to –0.04) 0.028 –0.23 (–0.33 to –0.13) <0.001
D Total hip aBMD –0.08 (–0.16 to 0.01) 0.081 –0.16 (–0.24 to –0.07) <0.001 –0.25 (–0.33 to –0.16) <0.001
D Total hip BMC –0.05 (–0.14 to 0.04) 0.300 –0.12 (–0.21 to –0.03) 0.011 –0.19 (–0.28 to –0.11) <0.001
D Femoral neck aBMD –0.08 (–0.17 to 0.01) 0.069 –0.16 (–0.24 to –0.07) <0.001 –0.21 (–0.29 to –0.13) <0.001
D Femoral neck BMC –0.02 (–0.11 to 0.07) 0.628 –0.13 (–0.22 to –0.04) 0.005 –0.18 (–0.26 to –0.10) <0.001
Analyses are adjusted for the baseline DXA parameter, baseline age, height, and total body lean and fat mass, and changes in lean and fat mass. Annual
changes in areal bone parameters were calculated as the absolute change from baseline to follow-up divided by years of follow-up. P1NP¼ procollagen
type I N-terminal propeptide; CTX ¼ C-terminal telopeptide of type I collagen; aBMD ¼ areal bone mineral density; BMC ¼ bone mineral content.
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important determinants of bone turnover in young adulthood,
with fat mass being inversely and sports activities being
positively associated with serum levels of bone turnover
markers. Furthermore, our longitudinal observations show
that bone loss in young adult men starts early after peak
bone mass attainment at all measurement sites, with higher
levels of bone turnover around peak bone mass age predicting
greater subsequent declines in aBMD.
In this population of young adult men, biochemical
markers of bone turnover were inversely associated with
age but remained remarkably high compared to levels
described in premenopausal women,(22,23) corroborating
previous observations that in men, bone turnover remains
high after peak bone mass attainment and reaches a nadir
only in the ﬁfth or sixth decade.(4–6) Bone turnover showed a
relatively strong familial resemblance with, independently of
age, 28% to 34% of the variance being located at the family
level. Although the present study was not designed to
discriminate whether this familial resemblance is due to
genetic or environmental factors, evidence from twin studies
suggested an important genetic component.(24–28) Moreover,
between-brother correlations of bone turnover markers in
older men were comparable to those in our population,
suggesting that the familial resemblance of bone turnover
cannot be entirely accounted for by shared environmental
factors.(29)
Fig. 2. Associations between baseline bone turnover markers and aBMD changes at the total body (minus head), spine, total hip, and femoral neck.
Annual aBMD changes were calculated as the absolute change from baseline to follow-up divided by years of follow-up. Bars and whiskers represent
mean annual aBMD change and standard error per quartile of baseline bone turnover markers. Quartile limits are 41.4mg/L, 49.3mg/L, and 62.8mg/L for
P1NP; 18.3mg/L, 21.5mg/L, and 25.7mg/L for osteocalcin; and 0.31mg/L, 0.42mg/L, and 0.52mg/L for CTX. ap< 0.05, bp< 0.01; cp< 0.001; analyses are
adjusted for baseline aBMD value, baseline age, height, and weight, and weight change. aBMD¼ areal bone mineral density.
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Partly corroborating our hypothesis, we observed positive
associations of bone turnover with lean mass and physical activity
during sports activities, but not with overall physical activity or
parameters reﬂecting muscle strength. Moreover, associations with
leanmasswere no longer signiﬁcant after adjustment for fatmass in
multivariate models, suggesting that mechanical loading is not a
majordeterminantof thehigh levelsofboneturnover inmenaround
peak bone mass age. In contrast, fat mass showed strong inverse
associations with biochemical markers of bone turnover, which is in
line with the lower levels of bone turnover observed in obese as
compared to non-obese children and adults,(30–32) and with the
observation that central adiposity was associated with lower bone
formation inpremenopausalwomen.(33)Giventhatmenandwomen
differ markedly in terms of body composition, with men having less
fat andmore leanmass as compared to women, these ﬁndingsmay
at least in part explain the higher levels of bone turnover markers in
young adult men as compared to women.
Themechanisms underlying the inverse association between fat
mass and bone turnover remain to be unraveled, although a
possible rolemaybeattributed toanalteredadipokine secretion. In
line herewith, we and other authors described inverse associations
between leptin levels and bone turnover markers.(30) Nonetheless,
as the role of leptin in bone homeostasis is complex and serum
leptin levels may merely be an index of the amount of fat mass
rather than being directly involved in its effects, its putative effects
on bone turnover merit further research.(34) Increases in body fat
arealsoaccompaniedbychanges inglucosemetabolism, including
increased fasting glucose levels and insulin resistance, which may
in turn affect bone turnover. Whereas some studies indeed
reported inverse associations of bone turnover markers with
HOMA-IR,(31,35)weandothers observednoassociationwithHOMA-
IRor fasting insulin levels,(30)and theobservedassociationbetween
P1NP and fasting glucose in our study lost signiﬁcance after
adjustment for body composition.
Although the timing is site- and sex-speciﬁc, peak bone mass
is generally assumed to be achieved during the second or third
decade of life.(36–39) To the best of our knowledge, our study is
the ﬁrst to speciﬁcally focus on the subsequent longitudinal
bone changes in young adult men, showing decreases in aBMD
at all measurement sites over a 12-year follow-up period. This is
in line with previous data showing that in bothmen andwomen,
trabecular bone loss starts early after peak bone mass
attainment, although cortical bone has been suggested to
remain fairly stable until midlife.(40,41) In addition, we showed
that higher levels of bone turnover at baseline were associated
with larger declines in aBMD and BMC, which is in parallel to
what has been described in middle-aged and elderly popula-
tions.(8,9,42) Conversely, in men at the end of puberty, high bone
turnover levels have been shown to be associated with larger
increases in bone mass and size.(7) The differential relationship
between levels of bone turnover markers and bone changes
before and after peak bone mass attainment is explained by the
fact that during growth, the net positive modeling and
remodeling balance leads to bone accrual, whereas after peak
bone mass attainment modeling declines and the remodeling
balance shifts towards resorption, thus leading to net bone
loss.(43,44) As the net changes associated with each remodeling
cycle are small, the rates of bone gain and bone loss are more
importantly driven by the remodeling rate.(45) Interestingly, we
observed the largest decreases in aBMD and BMC in the
youngest men. Therefore, we speculate that whereas the high
rates of bone turnover in young men, mediated by sports
activities and a favorable body composition, lead to an optimal
acquisition of peak bone mass during growth, they predict a
more rapid loss of bone mass soon thereafter.
Strengths of our study include the longitudinal design and the
relatively large andwell-characterized population-based sample of
healthy men. Limitations include the inclusion of only male and
primarily white subjects, the relatively low participation rate in the
longitudinal study, and the lack of intermittent follow-up time
points due to which possible initial increases in bone mass in the
youngest participants may have been missed. However, as the
largest bone losses were observed in the youngest men and
associations of bone turnover markers with bone loss were
consistent across the age range, the lattermay have had little or no
effect on our results. Although we identiﬁed signiﬁcant determi-
nants of bone turnover marker levels among a rather broad panel
of potential determinants, we acknowledge that they explain only
part of the variance in this population, and the persistence of high
levels of bone turnover markers in young adult men after
completion of bonematuration thus remains to be fully elucidated.
In conclusion, this study showed that in healthy adult men
around peak bone mass age, sports activities and body
composition, primarily fat mass, are the main identiﬁed
determinants of bone turnover. In turn, bone turnover at this
age is an important determinant of subsequent bone changes,
with higher levels of bone turnover markers being associated
with greater decreases in aBMD at several skeletal sites over a
12-year period. Thus, whereas high levels of bone turnover may
lead to larger increases in bone mass during growth, our
ﬁndings suggest that around peak bonemass age, they predict a
more rapid bone loss.
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